To: Proud Deplorable who wrote (23728 ) 5/22/2007 8:47:25 AM From: IRWIN JAMES FRANKEL Read Replies (4) | Respond to of 52153 >>Avandia is about to be banned. I doubt it. This came from IH and IF true is telling: Posted by: Cougar3 In reply to: None Date:5/22/2007 8:33:23 AM Post #of 47172 NEJM Article on Avandia (Following Post copied from another mb) "I read the NEJM article by Nissen. It made me wonder who the NEJM gets to review their articles these days. Relevant point: go to Table four, and look at the summary data. You will see that they "cleverly" showed the percent MI's for three separate groupings, and in each one, thecontrol group had a Lower % MI than the ones taking the drug. Now go to the bottom and look for the sum of all the groups and the percent MIs. It IS NOT THERE. However, the summary odds ratio is there! Now calculate the percent MI's for the total population in control versus drug. Ok, I have done this for you! Drug: 86 MIs / 14,371 patients %MI .60% Control: 72 MIs / 11,634 patients %MI .62% !!!!! Yes, you read correctly, the percent MI in the two croups was basically identical, control group slightly higher! Now, how in the world did they massage the data, to make 3 separate groups each show that the control had a lower percent MI, when the sum of those 3 groups is equal? Here is the secret: even though the percent of the 3rd group was lower than that of the drug group, the percent of that group was a larger proportion of the total control group, so when you add all the groups together the percentages are the same!! I would term this slimy data manipulation, which ought to have been seen by any competent reviewer. Now you know why they did not show this summary data, nor did they mention it. This shows me the study is completely bogus. I noticed they had to use "unusual" odds statistics to get a "significant" p value and the above data is probably why. Conclusion: Examination of the primary data (which this study did not do) will not likely validate this "newsworthy" NEJM article. If lots of law suits pop up and GSK drops in share price IMO it will be a "buy" just like MRK was after Vioxx. I will wait and see!"investorshub.com